Thermo Fisher Scientific collaborates with AstraZeneca and University of Nebraska Medical Center

Thermo Fisher Scientific, the world leader in serving science, today announced new collaborations of the Thermo Fisher Precision Medicine Science Center (PMSC) with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of innovative solutions for unmet needs in clinical biomarker discovery. The new alliances strengthen the PMSC’s mission of creating standardized workflows with pharma and academic partners to streamline the transition from biomarker research to clinical implementation, creating new opportunities for precision medicine.

Ongoing and planned studies with both AstraZeneca and the University of Nebraska Medical Center will utilize standardized plasma protein profiling workflows, including Thermo Fisher’s newly developed ultra-high throughput plasma protein profiling (uHTPPP) workflow, for biomarker discovery, for a range of conditions. The standardized workflows consist of automated sample preparation for untargeted and targeted methods in combination with the Thermo Scientific Orbitrap Exploris 480 and Thermo Scientific Orbitrap Exploris 240 mass spectrometers.

Precision medicine is becoming a greater area of interest across a range of different diseases and has, therefore, faced challenges effectively scaling to meet clinical needs. The goal of the Precision Medicine Science Center is to construct end-to-end workflow solutions that generate impactful data from discovery studies with large human cohorts and to harness the power of molecular profiling to improve the outcomes of patient care. Our ongoing work with AstraZeneca and the University of Nebraska Medical Center are paramount to realizing the potential of these technologies.”

Emily Chen, senior director, Precision Medicine Science Center, Thermo Fisher Scientific

Ventzi Hristova, senior scientist, dynamic omics, antibody discovery and protein engineering, R&D at AstraZeneca, said, “Powered by technological innovation, omics is proving to be one of the richest sources of data in all of science. Clinical proteomics is an emerging field aimed at improving patient care through the development of sensitive, high-throughput methods for in-depth proteomic characterization of clinical samples. This collaboration aims to evaluate and establish a model for clinical proteomics, using advanced sample processing and downstream analytical applications, that has the potential to help us identify new drug targets and biomarkers.”

Subsequently, the University of Nebraska Medical Center is collaborating with Thermo Fisher’s PMSC to utilize the company’s standardized plasma protein profiling workflows to analyze clinical samples in an aneurysm study. The study is supported by the National Institutes of Health-National Institute on Aging (NIH-NIA) and done in collaboration with Vanderbilt University, the University of Maryland and the University of Wisconsin.

Thermo Fisher’s mass spectrometry platform and workflow will allow us to analyze a large cohort of plasma samples and answer highly significant clinical questions. As a cardiovascular physiologist and proteomics expert, I am a bridge between mass spectrometry analyses and the clinical world and am very interested to see the results from this collaboration.”

Merry Lindsey, Ph.D., Chair and stokes-shackleford professor, Department of cellular and integrative physiology, director, center for heart and vascular research, University of Nebraska Medical Center

Bernard Timothy Baxter, MD, professor, department of surgery division of vascular surgery, University of Nebraska Medical Center, who is leading the NIH-NIA aneurysm study said, “There is a drastic need for this type of technology that can produce better indicators/blood tests and can tell us who has an undiagnosed aneurysm, and which aneurysms are likely to progress rapidly and need closer observation. Clinically, the current treatment plan for abdominal aortic aneurysms is to watch and wait. We image and when aneurysms reach a certain size threshold, we surgically repair them. Unfortunately, there are a number of patients who first realize there is a problem when they present with a ruptured aneurysm — the mortality in this situation exceeds 50%.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thermo Fisher Scientific Inc.. (2020, September 23). Thermo Fisher Scientific collaborates with AstraZeneca and University of Nebraska Medical Center. News-Medical. Retrieved on October 31, 2020 from https://www.news-medical.net/news/20200923/Thermo-Fisher-Scientific-collaborates-with-AstraZeneca-and-University-of-Nebraska-Medical-Center.aspx.

  • MLA

    Thermo Fisher Scientific Inc.. "Thermo Fisher Scientific collaborates with AstraZeneca and University of Nebraska Medical Center". News-Medical. 31 October 2020. <https://www.news-medical.net/news/20200923/Thermo-Fisher-Scientific-collaborates-with-AstraZeneca-and-University-of-Nebraska-Medical-Center.aspx>.

  • Chicago

    Thermo Fisher Scientific Inc.. "Thermo Fisher Scientific collaborates with AstraZeneca and University of Nebraska Medical Center". News-Medical. https://www.news-medical.net/news/20200923/Thermo-Fisher-Scientific-collaborates-with-AstraZeneca-and-University-of-Nebraska-Medical-Center.aspx. (accessed October 31, 2020).

  • Harvard

    Thermo Fisher Scientific Inc.. 2020. Thermo Fisher Scientific collaborates with AstraZeneca and University of Nebraska Medical Center. News-Medical, viewed 31 October 2020, https://www.news-medical.net/news/20200923/Thermo-Fisher-Scientific-collaborates-with-AstraZeneca-and-University-of-Nebraska-Medical-Center.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Thermo Fisher Scientific acknowledges the winners of 2020 TMT Research Grant Award